Phase two clinical trial demonstrates dramatic mobility gains in children with severe fibrous dysplasia

Fibrous dysplasia is a rare skeletal disorder in which normal bone is gradually replaced by weak fibro-osseous tissue, leading to fractures, pain, deformities, and severe mobility impairment. In many patients, diseased bone tissue produces excessive amounts of fibroblast growth factor-23 (FGF23), a hormone that causes phosphate loss through the kidneys.

Leave a Reply